Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amita Gupta

Showing results (171-180 of 328) with videos related to

Pageof 33
Sort By:
Biomed Research International|January 4, 2014
Pediatric tuberculosis in young children in India: a prospective studySanjay K Jain, Alvaro Ordonez, Aarti Kinikar, et al.
Pharmacogenetics and Genomics|August 21, 2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapineDavid W Haas, Anthony T Podany, Yajing Bao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2023
Adverse Pregnancy Outcomes Among Women with Human Immunodeficiency Virus Taking Isoniazid Preventive Therapy During the First TrimesterAmita Gupta, Michael D Hughes, Jorge Leon Cruz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2024
Reply to Kumar et alMatthew L Robinson, Julia Johnson, Shilpa Naik, et al.
Vaccine|February 4, 2014
Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairsAmita Gupta, Jyoti S Mathad, Wei-Teng Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2015
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T Podany, Yajing Bao, Susan Swindells, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 7, 2018
Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical TrialMcNeil Ngongondo, Sachiko Miyahara, Michael D Hughes, et al.
Emerging Infectious Diseases|October 27, 2004
Escherichia coli O157 cluster evaluationAmita Gupta, Susan B Hunter, Sally A Bidol, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|January 4, 2024
Tuberculin test using Indian indigenous purified-protein derivative (PPD) shows only moderate agreement with international standard PPDDevasahayam J Christopher, N Priya, Deepa Shankar, et al.
Pageof 33

Showing results (171-180 of 328) with videos related to

Sort By:
Pageof 33
Biomed Research International|January 4, 2014
Pediatric tuberculosis in young children in India: a prospective studySanjay K Jain, Alvaro Ordonez, Aarti Kinikar, et al.
Pharmacogenetics and Genomics|August 21, 2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapineDavid W Haas, Anthony T Podany, Yajing Bao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2023
Adverse Pregnancy Outcomes Among Women with Human Immunodeficiency Virus Taking Isoniazid Preventive Therapy During the First TrimesterAmita Gupta, Michael D Hughes, Jorge Leon Cruz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2024
Reply to Kumar et alMatthew L Robinson, Julia Johnson, Shilpa Naik, et al.
Vaccine|February 4, 2014
Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairsAmita Gupta, Jyoti S Mathad, Wei-Teng Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2015
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T Podany, Yajing Bao, Susan Swindells, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 7, 2018
Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical TrialMcNeil Ngongondo, Sachiko Miyahara, Michael D Hughes, et al.
Emerging Infectious Diseases|October 27, 2004
Escherichia coli O157 cluster evaluationAmita Gupta, Susan B Hunter, Sally A Bidol, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|January 4, 2024
Tuberculin test using Indian indigenous purified-protein derivative (PPD) shows only moderate agreement with international standard PPDDevasahayam J Christopher, N Priya, Deepa Shankar, et al.
Pageof 33